newswire, breaking biotechnology and pharma news

Thursday, February 10, 2011

BioSante's Senior V.P. Michael Snabes, MD, PhD, to Discuss Data From LibiGel® Safety Study

LINCOLNSHIRE, Ill. - February 10, 2011 ( newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports it will provide a LibiGel safety study update, in addition to supporting two clinical symposia, at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH).
An estimated 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting, hosted at the Doubletree Paradise Valley resort in Scottsdale, Arizona, February 10-13, 2011.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel� (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under an FDA Special Protocol Assessment (SPA). BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel�, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at:
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
For Media:
Alan Zachary
(312) 944-6784 ext. 316
Visit the BPAX showcase profile at
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on

No comments:

Post a Comment